Asia Pacific Autoimmune Diagnostics Market Share, Size, Forecast and Trends by 2021

07/ago/2017 12:01:46 Market Data Forecast Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The Asia Pacific Autoimmune Diagnostics Market was worth $ 2.09billion in 2016 and estimated to reach $ 2.54 billion by the end of 2021 with a growing potential of 4.00%. Asia Pacific is predicted to witness promising growth over the next five years. Constantly improving patient awareness levels and healthcare infrastructure in the evolving markets of India and China have opened up new avenues for the manufacturers to capitalize on.

 

Full report at: http://www.marketdataforecast.com/market-reports/Asia-Pacific-autoimmune-diagnostics-market-1193/

 

Autoimmune diseases is a hyper active immune response against its own body tissues and cells. Successful autoimmune disease awareness campaigns are boosting patients to seek clinical diagnostics even for symptoms such as gastrointestinal distress and fatigue. The rising incidence of primarily celiac disease, gastrointestinal autoimmune conditions also promotes testing.

 

Asia – Pacific market is mainly driven by High occurrence of auto immune disorders, increasing public awareness, improving healthcare infrastructure, increasing population. The key restraints that inhibiting the growth of the auto immune diagnostics market are high cost of treatment, growing rate of diagnostics errors and unavailability of skilled labour.

 

The Asia - Pacific Auto immune diagnostics Market is broadly categorized based on Test type into Complete Blood Count (CBC), Autoantibody Tests, and Antinuclear Antibody Tests, C - reactive protein (CRP), Comprehensive Metabolic panel, Urinalysis, Erythrocyte Sedimentation Rate (ESR) and others.

 

Based on Disease type the market is categorized into Localized auto immune disease diagnostics and systemic auto immune disease diagnostics. Local auto immune disease diagnostics is further classified into Graves’ disease, Hashimoto's Thyroiditis, Type 1 diabetes, Multiple Sclerosis, Psoriasis and Others. Systemic auto immune disease diagnostics is categorized into Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Ankylosing Spondylitis.

 

Based on End users into Hospitals, Research centres, and diagnostic laboratories and on the basis of geography, the Asia - Pacific Auto Immune Diagnostics market is analysed under various regions namely Japan, China, India and Australia.

 

Request sample: http://www.marketdataforecast.com/market-reports/Asia-Pacific-autoimmune-diagnostics-market-1193/request-sample

 

Some of the key players influencing the Asia – Pacific Autoimmune diagnostics market are Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli lilly, Glaxosmithkline Plc.

 

About Market Data Forecast:

 

The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com

 

Contact:

Abhishek Shukla

Sales Manager (International Business Development)

Market Data Forecast

Direct Line: +1-888-702-9626

Mobile: +91 998 555 0206

Mail: abhishek@marketdataforecast.com

Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/

 

View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl